TXMD · TherapeuticsMD, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on May 9, 2022; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TXMD
this stock
TherapeuticsMD, Inc.
|
$25.00M | +32.5% | +35.3% | — | 0.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$58.31B | +17.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$44.03B | -8.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$43.22B | +18.8% | +4.3% | 60.8 | 3.2% |
|
HLN
Haleon plc
|
$40.41B | -9.1% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on May 9, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TXMD | -3.6% | +3.9% | -3.6% | -0.9% | +32.5% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.4% | +5.6% | -21.4% | -0.6% | +20.4% |